• Corvus Pharmaceuticals Inc (NASDAQ: CRVS) has discontinued its Phase 3 study of mupadolimab for COVID-19 due to positive trends exhibited by COVID-19 vaccines in lowering infection and hospitalizations.

• The discontinuation is not related to any safety or efficacy issues, the company said in the press release.

• The company will continue to advance the development of mupadolimab in oncology, currently in a Phase 1/1b trial.

• As of June 30, Corvus had cash, cash equivalents, and marketable securities of approximately $66.5 million.

• With the discontinuation of the mupadolimab Phase 3 study in COVID-19, Corvus expects the full year 2021 net cash used in operating activities to be $35 million to $37 million, a decrease from the previously expected $46 million to $48 million and resulting in projected cash of $51.1 million to $53.1 million at December 31, 2021.

• Price Action: CRVS shares are trading lower by 11.6% at $2.06 in premarket on the last check Friday.

See more from Benzinga

• Click here for options trades from Benzinga

• Hutchmed's Stock Rises After EMA Validates Surufatinib Application For Neuroendocrine Tumors

• Merck Touts Encouraging Event-Free Survival For Keytruda Regime Over Placebo-Chemo Regime In Breast Cancer

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.